Stock Spotlight: Cheniere Energy Inc (NYSE:LNG)
About Cheniere Energy Inc
Cheniere Energy, Inc., an energy infrastructure company, primarily engages in the liquefied natural gas (LNG) related businesses in the United States. The company owns and operates the Sabine Pass LNG terminal in Cameron Parish, Louisiana; and the Corpus Christi LNG terminal near Corpus Christi, Texas. It also owns and operates the Creole Trail pipeline, a 94-mile natural gas supply pipeline that interconnects the Sabine Pass LNG Terminal with several interstate and intrastate pipelines; and the Corpus Christi pipeline, a 21-mile natural gas supply pipeline that interconnects the Corpus Christi LNG terminal with interstate and intrastate natural gas pipelines. In addition, the company engages in the LNG and natural gas marketing business. Cheniere Energy, Inc. was incorporated in 1983 and is headquartered in Houston, Texas.
Key Stats
Key Stats
Source: Yahoo Finance. Data as of 16/09/25.
Price Performance
Growth Potential
- Market leadership with the company remaining the largest U.S. LNG exporter (dominant facilities at Sabine Pass and Corpus Christi are being expanded with Stage 3 trains already delivering LNG and aiming to increase output by ~90 mtpa by end of decade), benefiting from high operating leverage and scale advantages with deep-water access, integrated pipeline systems and multi-decade export licenses.
- Strong contractual cashflows with ~85-99 % of volumes under long-term (most extending to 2040s), fixed/variable-fee (indexed to Henry Hub + liquefaction fee or fixed tolling fee) contracts, insulating earnings from spot-price volatility.
- Robust shareholder returns with the company having repurchased ~10% of its outstanding shares since announcing its 2020 vision plan in September 2022 (including ~13.8m shares for ~$2.3bn in 2024) with ~$3bn remaining on the current buyback authorization through 2027, and the Board remaining committed to growing its dividend by ~10% annually through the end of this decade (has been increased by >50% since its initiation in 2021), targeting a payout ratio of ~20% over time.
- Positive LNG market tailwinds with global demand for LNG expected to grow from ~420 mtpa in 2024 to ~650 mtpa by 2030, led by coal-to-gas switching in Asia, energy security concerns in Europe post-Russia war and increased demand for sustainable clean energy (solar/wind provide uncertainty) for datacentres/AI.
- Balance sheet deleveraging (debt reduced by ~$7bn since 2021) which has seen Fitch/Moody/S&P upgrade the credit ratings to BBB/Baa2/BBB, enhancing refinancing flexibility and lowering cost of capital.
Key Risks
- Any oversupply in the market (meaningful supply expected in 2026-28) could see spot prices fall below the company’s marginal cost on uncontracted volumes leading to weaker EBITDA growth and lower netbacks.
- High leverage and interest sensitivity with ~$22.8bn in long-term debt with rising interest rates or project disruptions potentially straining finances.
- Significant change at the senior management level (divisional CEOs).
- Project execution and cost overruns on Corpus Christi (Stage 3).
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.
Global energy risks are rising. Australia just committed $10.7 billion to respond. A closer look at the economic risks driving Australia’s push for greater fuel security.
The RBA has lifted rates to 4.35%. Here’s what it means for households, inflation, markets, sector performance and the outlook for Australian investors.
About The a2 Milk Co Ltd The a2 Milk Company Limited, together with its subsidiaries, sells A2-type protein type branded milk and related products in Australia, New Zealand, China, rest of Asia, and the United States. The company offers infant milk formula; other nutritional products and milk; manufactures and sells nutritional and ingredients products, as well as provides rent, royalty, and licensing services. It offers its products under the a2 Milk and a2 Platinum brands. The company was formerly known as A2 Corporation Limited and changed its name to The a2 Milk Company Limited in April 2014. The a2 Milk Company Limited was incorporated in 2000 and is based in Auckland, New Zealand. Source: EODHD Key Stats
About Meta Platforms Inc Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality (VR) headsets, and AI glasses in the United States, Canada, Europe, Asia-Pacific, and internationally. It operates through two segments, Family of Apps (FoA) and Reality Labs (RL). The FoA segment offers Facebook, which enables people to build community through feed, reels, stories, groups, marketplace, and other; Instagram that brings people closer through Instagram feed, stories, reels, live, and messaging; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; Meta AI, an assistant that's available across apps, as a stand-alone app, on AI glasses, and on the web; Threads, an application for text-based updates and public conversations; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact in a private way. The RL segment provides virtual and augmented reality products, including consumer hardware, software, and content that help people feel connected anytime and anywhere, as well as Meta Quest devices that enable social experiences across gaming, fitness, entertainment, and more. The segment also includes wearables such as AI glasses like Ray Ban Meta and Oakley Meta glasses, featuring Meta AI for advanced conversational and hands free interaction; and the Meta Ray Ban Display, which combines AI glasses with an integrated lens display and the Meta Neural Band, a wrist worn device using electromyography that lets people control their AI glasses through neuromuscular signals. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California. Source:EODHD Key Stats
About Amazon.com Inc Amazon.com, Inc. engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, fire tablets, fire TVs, echo, ring, blink, and eero; and develops and produces media content. In addition, the company offers programs that enable sellers to sell their products in its stores; and programs that allow authors, independent publishers, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, it provides compute, storage, Artificial intelligence, database, analytics, machine learning, and other services, as well as advertising services through programs, such as sponsored ads, display, and video advertising. Additionally, the company offers Amazon Prime, a membership program. The company's products offered through its stores include merchandise and content purchased for resale and products offered by third-party sellers. It serves consumers, sellers, developers, enterprises, content creators, advertisers, and employees. The company was incorporated in 1994 and is headquartered in Seattle, Washington. Source:EODHD Key Stats
Earnings may beat expectations, but guidance drives markets. Learn how to read forward outlooks, tone and signals to better interpret stock price reactions.
About Visa Inc. Visa Inc. operates as a payment technology company in the United States and internationally. The company operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. It also offers credit, debit, and prepaid card products; tap to pay, tokenization, and click to pay services; Visa Direct, a solution that facilitates the delivery of funds to eligible cards, bank accounts, and digital wallets; Visa B2B Connect, a multilateral business-to-business cross-border payments network; Visa Cross-Border Solution, a cross-border consumer payments solution; and Visa DPS that provides a range of value-added services, including fraud mitigation, dispute management, data analytics, campaign management, a suite of digital solutions, and contact center services. The company also provides acceptance solutions, which include Cybersource and Authorize.net that provides new and enhanced payment integrations with ecommerce platforms, enabling sellers and acquirers to offer tailored commerce experiences; risk and identity solutions, such as Visa Advanced Authorization, Visa Secure, Visa Consumer Authentication Service, Visa Protect Authentication Intelligence, and Visa Provisioning Intelligence; and Visa Consulting and Analytics, a payment consulting advisory services. It provides its services under the Visa, Visa Electron, Interlink, V PAY, and PLUS brands. The company serves merchants, financial institutions, and government entities. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California. Source:EODHD Key Stats
About Telix Pharmaceuticals Ltd Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Source:EODHD Key Stats
The UAE leaves OPEC on 1 May. Oil prices did not move. Here is why the near-term calm is masking a structural shift investors should not ignore.
Earnings are beating expectations, but the market is cautious. See what S&P 500 Q1 results reveal about market concentration and portfolio positioning.
